<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="perhaps, the likelihood of resistance. Abstract Because many aspects of" exact="viral infection" post="dynamics and inhibition are governed by stochastic processes, single-cell"/>
 <result pre="the likelihood of resistance. Abstract Because many aspects of viral" exact="infection" post="dynamics and inhibition are governed by stochastic processes, single-cell"/>
 <result pre="analysis reveals that each class of inhibitor interferes with the" exact="viral infection" post="cycle in a manner that can be distinguished by"/>
 <result pre="reveals that each class of inhibitor interferes with the viral" exact="infection" post="cycle in a manner that can be distinguished by"/>
 <result pre="which resistance will develop. Funding http://dx.doi.org/10.13039/100000060National Institute of Allergy and" exact="Infectious" post="Diseases AI120560 http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious Diseases"/>
 <result pre="resistance will develop. Funding http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious" exact="Diseases" post="AI120560 http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious Diseases AI120560"/>
 <result pre="Allergy and Infectious Diseases AI120560 http://dx.doi.org/10.13039/100000060National Institute of Allergy and" exact="Infectious" post="Diseases AI120560 http://dx.doi.org/10.13039/100000968American Heart Association 18POST33960071 INTRODUCTION Over the"/>
 <result pre="and Infectious Diseases AI120560 http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious" exact="Diseases" post="AI120560 http://dx.doi.org/10.13039/100000968American Heart Association 18POST33960071 INTRODUCTION Over the past"/>
 <result pre="AI120560 http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious Diseases AI120560 http://dx.doi.org/10.13039/100000968American" exact="Heart" post="Association 18POST33960071 INTRODUCTION Over the past few decades, the"/>
 <result pre="outbreaks of myriad RNA viruses, including West Nile virus, severe" exact="acute" post="respiratory syndrome coronavirus, Chikungunya virus, Ebola virus, Zika virus,"/>
 <result pre="of myriad RNA viruses, including West Nile virus, severe acute" exact="respiratory" post="syndrome coronavirus, Chikungunya virus, Ebola virus, Zika virus, and,"/>
 <result pre="myriad RNA viruses, including West Nile virus, severe acute respiratory" exact="syndrome" post="coronavirus, Chikungunya virus, Ebola virus, Zika virus, and, most"/>
 <result pre="viruses: enterovirus D68 (EV-D68) and enterovirus A71 (EV-A71) (1–6). Unfortunately," exact="viral" post="emergence has outpaced the discovery and development of compounds"/>
 <result pre="compound discovery. As a part of a study evaluating PV" exact="infection" post="dynamics on the single-cell level, we observed that a"/>
 <result pre="chain-terminating antiviral ribonucleotide selectively eliminates the most-fit members of the" exact="viral" post="population (7). This class of antiviral agent has always"/>
 <result pre="that amino acid substitutions in the active site of the" exact="viral" post="RNA polymerase conferring resistance to the antiviral ribonucleoside also"/>
 <result pre="natural ribonucleotides (9). Elimination of the most-fit members of the" exact="viral" post="population by an antiviral agent requires that resistance emerges"/>
 <result pre="describe a microfluidics device that can be used to produce" exact="complete" post="dose-response curves. We have used this device to compare"/>
 <result pre="antiviral therapies may have the potential to identify leads with" exact="limited" post="potential for development of resistance. RESULTS A device for"/>
 <result pre="antiviral agents Our initial foray into single-cell analysis of PV" exact="infection" post="dynamics used cell density to control single-cell occupancy of"/>
 <result pre="contains five independent zones, each containing 1140 wells for a" exact="total" post="of 5700 wells. The device mounts easily to the"/>
 <result pre="and fig. S1). Under conditions in which an inhibitor reduces" exact="infection" post="to 10%, ~100 infected cells will be observed using"/>
 <result pre="(different shades of green for the channel layer) for a" exact="total" post="of 5700 microwells. (B) Schematic of two wells of"/>
 <result pre="device contained single cells. Reevaluation of a PV polymerase inhibitor" exact="Viral" post="polymerases represent a well-established target of antiviral therapeutics. For"/>
 <result pre="of antiviral therapeutics. For example, cocktails used to treat human" exact="immunodeficiency" post="virus infection and hepatitis C virus (HCV) infection include"/>
 <result pre="antiviral therapeutics. For example, cocktails used to treat human immunodeficiency" exact="virus infection" post="and hepatitis C virus (HCV) infection include synthetic nucleoside"/>
 <result pre="therapeutics. For example, cocktails used to treat human immunodeficiency virus" exact="infection" post="and hepatitis C virus (HCV) infection include synthetic nucleoside"/>
 <result pre="example, cocktails used to treat human immunodeficiency virus infection and" exact="hepatitis" post="C virus (HCV) infection include synthetic nucleoside analogs targeting"/>
 <result pre="treat human immunodeficiency virus infection and hepatitis C virus (HCV)" exact="infection" post="include synthetic nucleoside analogs targeting reverse transcriptase and RNA-dependent"/>
 <result pre="and related compounds (13). In a previous study, we evaluated" exact="infections" post="that survived treatment when present at a concentration that"/>
 <result pre="when present at a concentration that reduces the number of" exact="infections" post="by 50% [median inhibitory concentration (IC50)]. To our surprise,"/>
 <result pre="express enhanced green fluorescent protein (PV-eGFP) at a multiplicity of" exact="infection" post="(MOI) of 0.5 plaque-forming units (PFU) per cell, pellet"/>
 <result pre="the approach is sensitive enough to acquire data for a" exact="complete" post="dose-response analysis (fig. S2B). A major advantage of the"/>
 <result pre="the time of half-maximum fluorescence, which correlates to replication speed;" exact="infection" post="time, which, to a first approximation, is the time"/>
 <result pre="a first approximation, is the time it takes for an" exact="infection" post="to go from start to finish akin to the"/>
 <result pre="parameter value measured in each cell. Instead of displaying the" exact="primary" post="data in a scatter plot (fig. S2, D and"/>
 <result pre="attributed to multiple factors, including speed and/or fidelity of the" exact="viral" post="polymerase, the capacity for the nucleoside to be converted"/>
 <result pre="3C protease inhibitor The observation that a subset of the" exact="viral" post="population was most sensitive to 2′-C-Me-A was unexpected but"/>
 <result pre="correlate to increased 2′-C-Me-AMP incorporation efficiency. Do inhibitors of other" exact="viral" post="enzymes exhibit the same selectivity? Proteases of retroviruses and"/>
 <result pre="measured the impact of rupintrivir on the establishment of PV" exact="infection" post="in HeLa S3 cells (Fig. 2A). The IC50 value"/>
 <result pre="control for all parameters: maximum (Fig. 2B), slope (Fig. 2C)," exact="infection" post="time (Fig. 2D), start point (Fig. 2E), and midpoint"/>
 <result pre="We conclude that not all antiviral agents interfere with the" exact="viral" post="population in the same manner or at the same"/>
 <result pre="or 20 nM rupintrivir were compared with that in the" exact="absence of" post="drug using a t test. A *P &amp;lt; 0.05"/>
 <result pre="the panels are as follows: (B) maximum, (C) slope, (D)" exact="infection" post="time, (E) start point, and (F) midpoint. hpi, hours"/>
 <result pre="fast and/or producing high levels of proteins, as observed in" exact="cancer" post="cells or in virus-infected cells. Seminal studies from the"/>
 <result pre="a clear, essential role for HSP90 in the production of" exact="infectious" post="PV virions (23). However, every step of the virus"/>
 <result pre="PV (23). The presence of GA reduced the number of" exact="infections" post="established by 22 ± 4%, with an IC50 value"/>
 <result pre="shown here would be concealed by experimental error (23). Because" exact="infection" post="is monitored by eGFP, which requires virus entry, genome"/>
 <result pre="or 100 nM GA were compared with that in the" exact="absence of" post="drug using a t test. **P &amp;lt; 0.005. Numerical"/>
 <result pre="the panels are as follows: (B) maximum, (C) slope, (D)" exact="infection" post="time, (E) start point, and (F) midpoint. Analysis of"/>
 <result pre="of GA (Fig. 3B), in contrast to the inhibitors targeting" exact="viral" post="proteins. Observation of a statistically significant difference in the"/>
 <result pre="significant difference in the distribution of the values for the" exact="infection" post="time parameter was concentration dependent (Fig. 3D). A statistically"/>
 <result pre="contrast to observations with GA, GS reduced the number of" exact="infections" post="established by 70 ± 14%, with an IC50 of"/>
 <result pre="of two drugs to exhibit greater efficacy (synergy) in preventing" exact="infection" post="in combination than observed when either drug is used"/>
 <result pre="or both at their IC50 values (Fig. 4A). In the" exact="absence of" post="drug, 34 ± 3% of cells in the device"/>
 <result pre="the panels are as follows: (B) maximum, (C) slope, (D)" exact="infection" post="time, (E) start point, and (F) midpoint. *P &amp;lt;"/>
 <result pre="based on changes to the phenomenological parameters used to describe" exact="infection" post="dynamics (fig. S6). We reasoned that principal component analysis"/>
 <result pre="from the other, as well as from outcomes in the" exact="absence of" post="drug. The mechanistically related, but chemically distinct, inhibitors of"/>
 <result pre="vector bisecting the parallelogram defined by the experiment in the" exact="absence of" post="either drug (control) and the experiments in the presence"/>
 <result pre="that the combination delays the start point and retards the" exact="infection" post="time. We conclude that single-cell analysis of antiviral therapeutics"/>
 <result pre="was performed using the mean values of the maximum, slope," exact="infection" post="time, start point, and midpoint from the various drug"/>
 <result pre="The top two principal components accounted for 94% of the" exact="total" post="variance. The light blue lines indicate the relationship between"/>
 <result pre="DISCUSSION The era of single-cell virology has begun (7, 32–35)." exact="Infection" post="outcomes in cells are determined, in part, by stochastic"/>
 <result pre="stochastic processes (36). For example, the presence and abundance of" exact="viral" post="restriction factors and viral replication promoting factors of the"/>
 <result pre="example, the presence and abundance of viral restriction factors and" exact="viral" post="replication promoting factors of the host are largely governed"/>
 <result pre="antiviral therapeutic, will not inform accurately the step(s) of the" exact="viral" post="lifecycle affected most by the perturbation. With this perspective"/>
 <result pre="revealed the unexpected finding that the most-fit members of the" exact="viral" post="population were most susceptible to this class of compounds"/>
 <result pre="this study. Our first-generation microfluidic device for on-chip investigation of" exact="viral infection" post="dynamics relied on cell density as the mechanism to"/>
 <result pre="study. Our first-generation microfluidic device for on-chip investigation of viral" exact="infection" post="dynamics relied on cell density as the mechanism to"/>
 <result pre="(Fig. 1 and fig. S1). The enhanced occupancy enabled the" exact="complete" post="characterization of antiviral therapeutics by permitting the acquisition of"/>
 <result pre="complete characterization of antiviral therapeutics by permitting the acquisition of" exact="complete" post="dose-response curves (e.g., Fig. 2A). The three classes of"/>
 <result pre="2A). The three classes of antiviral therapeutics chosen target a" exact="viral" post="polymerase (2′-C-Me-A; fig. S2), a viral protease (rupintrivir; Fig."/>
 <result pre="therapeutics chosen target a viral polymerase (2′-C-Me-A; fig. S2), a" exact="viral" post="protease (rupintrivir; Fig. 2), or a host factor, HSP90,"/>
 <result pre="parameters with correlates to traditional parameters for assessment of the" exact="viral" post="lifecycle. The major finding of this study is that"/>
 <result pre="of the difference of each parameter in the presence and" exact="absence of" post="the antiviral agent to visualize the signature for the"/>
 <result pre="of this population of viruses. These same members of the" exact="viral" post="population were sensitive to rupintrivir (fig. S6C). In this"/>
 <result pre="(fig. S6C). In this case, at concentrations equivalent to or" exact="lower" post="than the IC50, binding is driven by the concentration"/>
 <result pre="these conditions. A comparable analysis using the start point and" exact="infection" post="time provided an even greater distinction between the three"/>
 <result pre="observation that rupintrivir retarded the time it took to establish" exact="infection" post="and to complete replication (fig. S6F). This observation may"/>
 <result pre="retarded the time it took to establish infection and to" exact="complete" post="replication (fig. S6F). This observation may reflect the role"/>
 <result pre="the first to analyze a range of antiviral therapeutics on" exact="viral infection" post="dynamics at the single-cell level. The resolution afforded by"/>
 <result pre="first to analyze a range of antiviral therapeutics on viral" exact="infection" post="dynamics at the single-cell level. The resolution afforded by"/>
 <result pre="reagents HeLa and HeLa S3 cells were obtained from the" exact="American" post="Type Culture Collection and maintained in Dulbecco’s modified Eagle’s"/>
 <result pre="Kit (Qiagen, Netherlands). With the linearized plasmid as the template," exact="viral" post="RNA was transcribed at 37°C for 5.5 hours in"/>
 <result pre="a Typhoon 8600 scanner (Promega, USA). Then, 5 μg of" exact="viral" post="RNA was used to transfect HeLa cells cultured at"/>
 <result pre="Co. (St. Louis, MO, USA). 2′-C-Me-A was obtained from Carbosynth" exact="Limited" post="(Compton, Berkshire, UK). Solutions of GA and GS in"/>
 <result pre="incubation system (Tokai, Japan) adapted to a Nikon Eclipse Ti" exact="inverted" post="microscope (Nikon, Japan) equipped with a ProScan II motorized"/>
 <result pre="setup, bright-field and fluorescence images of the microwells were automatically" exact="acquired" post="every 30 min from 2.5 to 24 hours postinfection."/>
 <result pre="obtained. With a customized package of R, the maximum, slope," exact="infection" post="time, start point, and midpoint were derived for each"/>
 <result pre="A.W. is the recipient of a postdoctoral fellowship from the" exact="American" post="Heart Association (no. 18POST33960071). Author contributions: W.L. and C.E.C."/>
 <result pre="is the recipient of a postdoctoral fellowship from the American" exact="Heart" post="Association (no. 18POST33960071). Author contributions: W.L. and C.E.C. designed"/>
 <result pre="SARS study group, Coronavirus as a possible cause of severe" exact="acute" post="respiratory syndrome. Lancet361, 1319–1325 (2003).12711465 3BurtF. J., RolphM. S.,"/>
 <result pre="study group, Coronavirus as a possible cause of severe acute" exact="respiratory" post="syndrome. Lancet361, 1319–1325 (2003).12711465 3BurtF. J., RolphM. S., RulliN."/>
 <result pre="K., FormentyP., Van HerpM., GüntherS., Emergence of Zaire Ebola virus" exact="disease" post="in Guinea. N. Engl. J. Med.371, 1418–1425 (2014).24738640 5CamposG."/>
 <result pre="SchuffeneckerI., MirandA., Leruez-VilleM., BassiC., AubartM., MoulinF., Lévy-BruhlD., HenquellC., LinaB., DesguerreI.," exact="Severe" post="paediatric conditions linked with EV-A71 and EV-D68, France, May"/>
 <result pre="O., HuangT. J., CameronC. E., Single-cell virology: On-chip investigation of" exact="viral infection" post="dynamics. Cell Rep.21, 1692–1704 (2017).29117571 8FengJ. Y., Addressing the"/>
 <result pre="HuangT. J., CameronC. E., Single-cell virology: On-chip investigation of viral" exact="infection" post="dynamics. Cell Rep.21, 1692–1704 (2017).29117571 8FengJ. Y., Addressing the"/>
 <result pre="MigliaccioG., De FrancescoR., KuoL. C., MacCossM., OlsenD. B., Inhibition of" exact="hepatitis" post="C virus RNA replication by 2’-modified nucleoside analogs. J."/>
 <result pre="2’-modified nucleoside analogs. J. Biol. Chem.278, 11979–11984 (2003).12554735 10AndinoR., DomingoE.," exact="Viral" post="quasispecies. Virology479-480, 46–51 (2015).25824477 11CihlarT., RayA. S., Nucleoside and"/>
 <result pre="MosleyR. T., RossB. S., Nucleoside, nucleotide, and non-nucleoside inhibitors of" exact="hepatitis" post="C virus NS5B RNA-dependent RNA-polymerase. J. Med. Chem.55, 2481–2531"/>
 <result pre="LucianiF., WhiteP. A., LloydA. R., BullR. A., Inhibitors of the" exact="hepatitis" post="C virus polymerase, mode of action and resistance. Viruses7,"/>
 <result pre="MorreyJ. D., JulanderJ. L., FurmanP. A., OttoM. J., Inhibition of" exact="hepatitis" post="C replicon RNA synthesis by β-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine: A specific inhibitor"/>
 <result pre="C replicon RNA synthesis by β-D-2’-deoxy-2’-fluoro-2’-C-methylcytidine: A specific inhibitor of" exact="hepatitis" post="C virus replication. Antivir. Chem. Chemother.17, 79–87 (2006).17042329 15WlodawerA.,"/>
 <result pre="Viruses1, 1209–1239 (2009).21994591 17de LeuwP., StephanC., Protease inhibitor therapy for" exact="hepatitis" post="C virus-infection. Expert Opin. Pharmacother.19, 577–587 (2018).29595065 18WangH.-M., LiangP.-H.,"/>
 <result pre="RombautB., De ClercqE., NeytsJ., Potential use of antiviral agents in" exact="polio" post="eradication. Emerg. Infect. Dis.14, 545–551 (2008).18394270 20BinfordS. L., MaldonadoF.,"/>
 <result pre="Broad action of Hsp90 as a host chaperone required for" exact="viral" post="replication. Biochim. Biophys. Acta1823, 698–706 (2012).22154817 23GellerR., VignuzziM., AndinoR.,"/>
 <result pre="inhibitors: Multi-targeted antitumor effects and novel combinatorial therapeutic approaches in" exact="cancer" post="therapy. Curr. Med. Chem.16, 3081–3092 (2009).19689285 26SideraK., PatsavoudiE., HSP90"/>
 <result pre="(2009).19689285 26SideraK., PatsavoudiE., HSP90 inhibitors: Current development and potential in" exact="cancer" post="therapy. Recent Pat. Anticancer Drug Discov.9, 1–20 (2014).23312026 27RoeS."/>
 <result pre="exhibits potent antitumor activity and a superior safety profile for" exact="cancer" post="therapy. Mol. Cancer Ther.11, 475–484 (2012).22144665 29PrinceT. L., KijimaT.,"/>
 <result pre="activity and a superior safety profile for cancer therapy. Mol." exact="Cancer" post="Ther.11, 475–484 (2012).22144665 29PrinceT. L., KijimaT., TatokoroM., LeeS., TsutsumiS.,"/>
 <result pre="V. Soriano, S. Zeuzem, Antiviral combination therapy for treatment of" exact="chronic hepatitis" post="B, hepatitis C, and human immunodeficiency virus infection. In"/>
 <result pre="Soriano, S. Zeuzem, Antiviral combination therapy for treatment of chronic" exact="hepatitis" post="B, hepatitis C, and human immunodeficiency virus infection. In"/>
 <result pre="Zeuzem, Antiviral combination therapy for treatment of chronic hepatitis B," exact="hepatitis" post="C, and human immunodeficiency virus infection. In Antiviral Strategies"/>
 <result pre="for treatment of chronic hepatitis B, hepatitis C, and human" exact="immunodeficiency" post="virus infection. In Antiviral Strategies (Springer, 2009), vol.189, pp."/>
 <result pre="treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency" exact="virus infection." post="In Antiviral Strategies (Springer, 2009), vol.189, pp. 321–346. 32TimmA."/>
 <result pre="WarrickJ. W., YinJ., Quantitative profiling of innate immune activation by" exact="viral infection" post="in single cells. Integr. Biol.9, 782–791 (2017). 33RamjiR., WongV."/>
 <result pre="W., YinJ., Quantitative profiling of innate immune activation by viral" exact="infection" post="in single cells. Integr. Biol.9, 782–791 (2017). 33RamjiR., WongV."/>
 <result pre="34CombeM., GarijoR., GellerR., CuevasJ. M., SanjuánR., Single-cell analysis of RNA" exact="virus infection" post="identifies multiple genetically diverse viral genomes within single infectious"/>
 <result pre="GarijoR., GellerR., CuevasJ. M., SanjuánR., Single-cell analysis of RNA virus" exact="infection" post="identifies multiple genetically diverse viral genomes within single infectious"/>
 <result pre="Single-cell analysis of RNA virus infection identifies multiple genetically diverse" exact="viral" post="genomes within single infectious units. Cell Host Microbe18, 424–432"/>
 <result pre="virus infection identifies multiple genetically diverse viral genomes within single" exact="infectious" post="units. Cell Host Microbe18, 424–432 (2015).26468746 35RussellA. B., TrapnellC.,"/>
 <result pre="(2015).26468746 35RussellA. B., TrapnellC., BloomJ. D., Extreme heterogeneity of influenza" exact="virus infection" post="in single cells. ELife7, e32303 (2018).29451492 36HeldtF. S., KupkeS."/>
 <result pre="35RussellA. B., TrapnellC., BloomJ. D., Extreme heterogeneity of influenza virus" exact="infection" post="in single cells. ELife7, e32303 (2018).29451492 36HeldtF. S., KupkeS."/>
 <result pre="and stochastic modelling unveil large cell-to-cell variability in influenza A" exact="virus infection." post="Nat. Commun.6, 8938 (2015).26586423 37RajA., van OudenaardenA., Nature, nurture,"/>
</results>
